• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » ICON Trims Revenue Outlook, Boosts Profits

ICON Trims Revenue Outlook, Boosts Profits

January 19, 2009
CenterWatch Staff

While Kendle and Parexel became the latest contract research organizations (CROs) to lower their profit and revenue outlooks last week, one CRO actually increased its earnings expectations.

Dublin, Ireland-based ICON increased its 2008 earnings per diluted share (EPS) range to $1.27 to $1.29, up from the prior guidance of $1.23 to $1.26, an increase that was driven by improving margins, according to ICON CEO Peter Gray in an investor conference call last week. This EPS increase, however, comes with a reduction in ICON’s 2008 revenue guidance.

“For 2008 overall, we expect to report revenues in the range of $862 to $865 million, which is a modest reduction in previous guidance reflecting the impact of currency volatility over the last six months,” Gray said.

In July, ICON’s revenue for 2008 was estimated to be in the range of $870 to $890 million. For 2009, the CRO expects revenues to be in the range of $930 million to $980 million, representing 8% to 13% growth over 2008. Gray told investors that ICON’s 2009 profit margin is expected to be in the range of 12% to 12.5%—up from 11.5% to 11.8% in— 2008, “assuming a more stable currency.”

Elsewhere in the industry, global CRO Kendle lowered its full-year 2008 guidance last week, citing the negative effects of foreign exchange rates, and Waltham, Mass.-based Parexel announced that an unexpected contract termination and related bad debt will reduce its consolidated service revenue for the second half of its 2009 fiscal year by $6 million.

Following ICON’s investor conference call, ICON’s shares rose 6.2% to $22.53, but shares went down with the rest of the stock market to $21.45 at week’s end.

ICON also announced the completion of its acquisition of the remaining 30% stake in Beacon Bioscience, a medical imaging CRO in which ICON purchased a 70% stake in July 2004. Beacon changed its name to ICON Medical Imaging in 2007.

“ICON Medical Imaging has become a leader in its field,” Gray said in a company statement. “We believe that now is the right time to complete the acquisition of the remaining stake in the business.”

In 2008, ICON opened up six global offices, completed three acquisitions, including Beacon, and opened a new central lab in India.

“It’s been an active year for us in terms of strategically developing the organization,” Gray told investors.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing